Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1998 May;42(5):1274-7.
doi: 10.1128/AAC.42.5.1274.

In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers

P C Fuchs  1 , A L Barry, S D Brown
Affiliations
Comparative Study

In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers

P C Fuchs et al. Antimicrob Agents Chemother. 1998 May.

Abstract

Clinafloxacin was more active than ciprofloxacin against 4,213 aerobic and facultative anaerobic bacterial isolates from 10 medical centers, as tested by broth microdilution and disk diffusion methods. The percentage of 201 anaerobes susceptible to clinafloxacin by broth microdilution was comparable to cefoxitin. Our data support the proposed disk diffusion interpretive criteria for aerobic bacteria with 5-microg clinafloxacin disks.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Scattergram of clinafloxacin MICs (ordinate) and disk diffusion zone diameters (abscissa) for 4,057 aerobic clinical isolates. Horizontal lines represent proposed MIC breakpoints; vertical lines represent the corresponding zone diameter breakpoints.
See this image and copyright information in PMC

References

    1. Bron N J, Dorr M B, Mant T G, Webb C L, Vassos A B. The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects. J Antimicrob Chemother. 1996;38:1023–1029. - PubMed
    1. Carlyn C J, Doyle L J, Knapp C C, Ludwig M D, Washington J A. Activities of three investigational fluoroquinolones (BAY y 3118, DU-6859a, and clinafloxacin) against Neisseria gonorrhoeae isolates with diminished susceptibilities to ciprofloxacin and ofloxacin. Antimicrob Agents Chemother. 1995;39:1606–1608. - PMC - PubMed
    1. Cohen M A, Yoder S L, Huband M D, Roland G E, Courtney C L. In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci. Antimicrob Agents Chemother. 1995;39:2123–2127. - PMC - PubMed
    1. Fuchs P C, Barry A L, Pfaller M A, Allen S D, Gerlach E H. Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrob Agents Chemother. 1991;35:764–766. - PMC - PubMed
    1. Harrington G D, Zarins L T, Ramsey M A, Bradley S F, Kauffman C A. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin. Diagn Microbiol Infect Dis. 1995;21:27–31. - PubMed

Publication types

MeSH terms

LinkOut - more resources